Creative Medical Technology Holdings Inc(CELZ) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 4:00 PM ET (Korea 11/3 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.78 | Insider Own | 15.7% | Shs Outstand | 6.5M | Perf Week | -12.43% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 25.42% | Insider Trans | - | Shs Float | 5.6M | Perf Month | -34.12% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.24 | Inst Own | 5.66% | Short Float | 1.48% | Perf Quarter | -5.01% |
| Income | -0.01B | P/S | - | EPS this Y | 53.17% | Inst Trans | 2.1% | Short Ratio | 0.01 | Perf Half Y | -71.27% |
| Sales | 0.00B | P/B | 0.47 | EPS next 5Y | 30.39% | ROA | -73.3% | Short Interest | 0.08M | Perf YTD | -68.19% |
| Book/sh | 1.33 | P/C | 0.47 | EPS past 3/5Y | 35.28% 66.83% | ROE | -78.03% | 52W High | -86.79% ($4.72) | Perf Year | -80.33% |
| Cash/sh | 1.34 | P/FCF | - | Sales past 3/5Y | -59.24% -48.43% | ROIC | -69.79% | 52W Low | 0.56% ($0.62) | Perf 3Y | -85.83% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 44.01% | Gross Margin | -3725.83% | Volatility(W/M) | 9.54% 7.16% | Perf 5Y | -99.13% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -50% | Oper. Margin | -208004.4% | ATR (14) | 0.07 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 12.91 | EPS Q/Q | 14.52% | Profit Margin | -201355.37% | RSI (14) | 29.79 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.91 | Sales Q/Q | - | SMA20 | -18.47% ($0.76) | Beta | 2 | Target Price | $20 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -31.99% ($0.91) | Rel Volume | 0.03 | Prev Close | $0.65 |
| Employees | 4 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -60.31% ($1.56) | Avg Volume(3M) | 6.65M | Price | $0.62 |
| IPO | 2015/11/6 | Option/Short | No/Yes | Trades | 280 | Volume | 224,683 | Change | -4.81% |
🧬 Creative Medical Technology Holdings () is a clinical-stage regenerative medicine company targeting Type 1 diabetes, chronic lower back pain (degenerative disc disease), and autoimmune/immune disorders through its adult and placenta-derived stem cell technologies. Centered on the ImmCelz immune reprogramming platform and the CELZ-201 (olastrocel) series, the company operates a multi-pipeline portfolio. It is a micro-cap name with key clinical events on the horizon, including ADAPT (lower back pain) and CREATE-1 (Type 1 diabetes) trials.
Over the past 1 year, on the lower side
87% below its 1-year high.
Traded less than usual. That is 3% of its average volume.
CELZ has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +53.2% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.1%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #550 of 597 in the industry
Based on market cap of $4M.
CRIS#548 Curis Inc $4M PER - 
NCNA#549 NuCana plc ADR $4M PER - CELZ#550 Creative Medical Technology Holdings Inc $4M PER - 
DRMA#551 Dermata Therapeutics Inc $4M PER - 
CVKD#552 Cadrenal Therapeutics Inc $4M PER - 
FAQ
What kind of company is CELZ?
CELZ belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CELZ?
The market cap of CELZ is approximately $4M, ranking 5,659 within its sector.
What is the 52-week high and low for CELZ?
CELZ has recorded a 52-week high of $4.72 and a low of $0.62.
